FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Lenalidomide is used to treat cancer and also some anaemia disorders
The group has a total of 320 ANDA approvals
This is the first of its kind vaccine for Covid 19 to get the go-ahead
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
It’s an AB-rated generic therapeutic version of Durezol
The company is eligible for 12 months exclusivity from launch
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Subscribe To Our Newsletter & Stay Updated
